Key Highlights

  • NBTX shares fell 9.60% intraday to $39.37, down from Friday's close of $43.55.
  • The decline follows fourth-quarter and fiscal 2025 results showing Earnings Per Share below Wall Street forecasts despite a Revenue beat.
  • Trading Volume was roughly 1.6 times average, reflecting a significant reaction to the earnings miss.
  • The decline extends a post-earnings pullback that began in the prior session.

Earnings Miss Drives Sharp Decline

Nanobiotix S.A. (NASDAQ:NBTX) shares fell sharply in Monday's session on heavy volume, roughly 1.6 times the average, after the company's fourth-quarter and fiscal 2025 earnings report showed earnings per share coming in below Wall Street forecasts despite a revenue beat, extending a post-earnings pullback that began in the prior session.

Nanobiotix is a Paris-based, late clinical-stage biotechnology company pioneering physics-based nanotherapeutics to improve outcomes for cancer patients. Its lead candidate, NBTXR3, is a sterile aqueous suspension of crystalline hafnium oxide nanoparticles designed for intratumoral injection to enhance the efficacy of radiotherapy against tumors, with development spanning soft tissue sarcoma, head and neck, liver, pancreatic, esophageal, rectal, and non-small cell lung cancers.

The decline stands in contrast to a broadly strong biotech tape, where the iShares Biotechnology ETF has hit record highs and healthcare remains one of the market's heating-up sectors, underscoring that today's investor disappointment is company-specific rather than sector-driven as the market digests weaker-than-expected profitability metrics from the small-cap name.

Strategic Partnerships Continue to Support Development

Nanobiotix carries a market Capitalization of approximately $1.99 billion. The stock does not currently report a forward or trailing price-to-earnings ratio given its net loss position, with earnings per share at negative $0.59. The company's 52-week range spans $8.03 to $57.14.

The company has forged strategic partnerships, including a major collaboration with Johnson & Johnson, now advancing as JNJ-1900, for global development of NBTXR3, and a regional Partnership with LianBio to commercialize the therapy across Greater China, South Korea, Singapore, and Thailand. Nanobiotix is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market since December 2020.

Profitability Metrics Remain Under Scrutiny

Nanobiotix's sharp decline reflects investor focus on the company's profitability shortfall despite the revenue beat, a company-specific disappointment set against an otherwise strong biotech sector backdrop. Investors will likely watch for progress updates from its Johnson & Johnson and LianBio partnerships in coming quarters.